PTG1-plus, Polytheragene’s leading product, is chosen by Généthon to produce the gene therapy product (AAV8 encoding human microdystrophin) for the GNT0004 clinical trial for Duchenne muscular dystrophy (https://www.afm-telethon.fr/fr).
PTG1-plus, Polytheragene’s leading product, is chosen by Généthon to produce the gene therapy product (AAV8 encoding human microdystrophin) for the GNT0004 clinical trial for Duchenne muscular dystrophy (https://www.afm-telethon.fr/fr).